文献速递胸部肿瘤

老年与年轻III期非小细胞肺癌患者同步放化疗个体患者数据汇总分析:来自美国国家癌症研究所合作组研究

Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
PubMed 文献 · J Clin Oncol · 2017-05-11

汇总1990至2012年美国国家癌症研究所支持的16项II/III期同步放化疗试验的个体患者数据,比较≥70岁老年与<70岁年轻III期非小细胞肺癌患者。老年患者总生存更差(校正HR 1.17,95%CI 1.07-1.29),无进展生存相似,≥3级不良事件更高(校正OR 1.38,95%CI 1.10-1.74),5级不良事件9% vs 4%。

要点

  • 老年患者总生存更差,校正HR 1.17(95%CI 1.07-1.29)。
  • 老年与年轻患者无进展生存相似,校正HR 1.00(95%CI 0.91-1.09)。
  • 老年患者≥3级不良事件更高,校正OR 1.38(95%CI 1.10-1.74)。

核心结论

  • 老年患者在接受同步放化疗的试验中总生存更差、毒性更多、治疗期间死亡比例更高。

研究设计与样本

  • 汇总1990至2012年美国国家癌症研究所支持的合作组16项II期或III期试验的个体患者数据,纳入接受单纯同步放化疗或联合巩固/诱导化疗的III期非小细胞肺癌患者。
  • 共2768例年轻患者和832例老年患者(年龄≥70岁)。
  • 采用单因素和多因素脆弱Cox模型估计生存风险比(HR),采用单因素和多因素广义线性混合效应模型估计不良事件比值比(OR)。

主要发现

  • 老年患者总生存更差:未校正HR 1.20(95%CI 1.09-1.31),多因素校正HR 1.17(95%CI 1.07-1.29)。
  • 老年与年轻患者无进展生存相似:未校正HR 1.01(95%CI 0.93-1.10),多因素校正HR 1.00(95%CI 0.91-1.09)。
  • 老年患者≥3级不良事件更高:未校正OR 1.35(95%CI 1.07-1.70),多因素校正OR 1.38(95%CI 1.10-1.74)。
  • 5级不良事件老年患者9% vs 年轻患者4%(P<.01)。
  • 老年患者完成治疗比例更低(47% vs 57%,P<.01),因不良事件终止治疗更多(20% vs 13%,P<.01),治疗期间死亡更多(7.8% vs 2.9%,P<.01),拒绝进一步治疗更多(5.8% vs 3.9%,P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non-small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients and Methods Individual patient data were collected from 16 phase II or III trials conducted by US National Cancer Institute-supported cooperative groups of concurrent chemoradiotherapy alone or with consolidation or induction chemotherapy for stage III non-small-cell lung cancer from 1990 to 2012. Overall survival (OS), progression-free survival, and AEs were compared between patients age ≥ 70 (elderly) and those younger than 70 years (younger). Unadjusted and adjusted hazard ratios (HRs) for survival time and CIs were estimated by single-predictor and multivariable frailty Cox models. Unadjusted and adjusted odds ratio (ORs) for AEs and CIs were obtained from single-predictor and multivariable generalized linear mixed-effect models. Results A total of 2,768 patients were classified as younger and 832 as elderly. In unadjusted and multivariable models, elderly patients had worse OS (HR, 1.20; 95% CI, 1.09 to 1.31 and HR, 1.17; 95% CI, 1.07 to 1.29, respectively). In unadjusted and multivariable models, elderly and younger patients had similar progression-free survival (HR, 1.01; 95% CI, 0.93 to 1.10 and HR, 1.00; 95% CI, 0.91 to 1.09, respectively). Elderly patients had a higher rate of grade ≥ 3 AEs in unadjusted and multivariable models (OR, 1.35; 95% CI, 1.07 to 1.70 and OR, 1.38; 95% CI, 1.10 to 1.74, respectively). Grade 5 AEs were significantly higher in elderly compared with younger patients (9% v 4%; P < .01). Fewer elderly compared with younger patients completed treatment (47% v 57%; P < .01), and more discontinued treatment because of AEs (20% v 13%; P < .01), died during treatment (7.8% v 2.9%; P < .01), and refused further treatment (5.8% v 3.9%; P = .02). Conclusion Elderly patients in concurrent chemoradiotherapy trials experienced worse OS, more toxicity, and had a higher rate of death during treatment than younger patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stinchcombe TE, Zhang Y, Vokes EE, et al. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017. PMID: 28493811. doi:10.1200/JCO.2016.71.4758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。